¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"symptomatic myeloid metaplasia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® symptomatic therapy ÇÑ±Û ´ëÁõ¿ä¹ý
¼³¸í   
  º´ÀÇ ¿øÀÎÀ» Ã£¾Æ ¾ø¾Ö±â °ï¶õÇÑ »óȲ¿¡¼­, °ÑÀ¸·Î ³ªÅ¸³­ º´ÀÇ Áõ»ó¿¡ ´ëÀÀÇÏ¿© Ã³Ä¡¸¦ Çϴ ġ·á¹ý. ¿­ÀÌ ³ôÀ» ¶§¿¡ ¾óÀ½ÁָӴϸ¦ ´ë°Å³ª ÇØ¿­Á¦¸¦ ½á¼­ ¿­À» ³»¸®°Ô Çϴ µûÀ§°¡ ÀÌ¿¡ ¼ÓÇÑ´Ù. 
¿µ¹® metaplasia ÇÑ±Û È­»ý
¼³¸í   
  ´Ù¸£°Ô º¯ÇѴٴ ¶æÀ¸·Î ¾²ÀδÙ. ¼º¼÷µÈ Á¶Á÷¿¡¼­ ´Ù¸¥ Á¾·ùÀÇ ¼º¼÷Á¶Á÷À¸·Î º¯Çϴ °ÍÀ» ¸»ÇÑ´Ù. ´ë°³´Â Áö¼ÓÀû Àڱؿ¡ ÀÇÇÏ¿© Á» ´õ ¾ÈÁ¤µÈ ¼¼Æ÷ÇüÅ·Πº¯È­Çϴ °ÍÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agnogenic myeloid metaplasia
    ¿øÀκҸí°ñ¼öÈ­»ý
  • myeloid metaplasia
    °ñ¼öÈ­»ý
  • symptomatic
    1. Áõ»ó°ü·Ã- 2. ´ëÁõ-
  • symptomatic therapy
    ´ëÁõ¿ä¹ý
  • symptomatic treatment
    Áõ»óÄ¡·á, ´ëÁõ¿ä¹ý
  • myeloid
    °ñ¼ö¸ð¾ç-, °ñ¼ö¼º
  • myeloid cell
    °ñ¼ö¼¼Æ÷
  • apocrine metaplasia
    ¾ÆÆ÷Å©¸°È­»ý
  • metaplasia
    È­»ý
  • squamous metaplasia
    ÆíÆò»óÇÇÈ­»ý
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • symptomatic therapy
    ´ëÁõ¿ä¹ý
  • metaplasia
    È­»ý
  • squamous metaplasia
    ÆíÆò»óÇÇÈ­»ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agnogenic myeloid metaplasia
    ¿øÀκҸí°ñ¼öÈ­»ý
  • myeloid metaplasia
    °ñ¼öÈ­»ý
  • symptomatic
    Áõ»ó-
  • symptomatic therapy
    ´ëÁõ¿ä¹ý
  • symptomatic treatment
    (¢¡expectant treatment) ±â´ëÄ¡·á
  • myeloid cell
    (¢¡marrow cell) °ñ¼ö¼¼Æ÷
  • myeloid
    °ñ¼ö¸ð¾ç-
  • apocrine metaplasia
    ¾ÆÆ÷Å©¸°È­»ý
  • metaplasia
    È­»ý
  • squamous metaplasia
    ÆíÆò»óÇÇÈ­»ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agnogenic myeloid metaplasia
    ¿øÀκҸíÀÇ °ñ¼öÈ­»ýÁõ.
  • agnogenic(idiopathic) myeloid metaplasia
    ¿øÀκҸí(Ư¹ß¼º) °ñ¼öÈ­»ýÁõ(ê«ì×ÝÕÙ¥ ÍéâÐûùßæñø)
  • apocrine metaplasia
    ¾ÆÆ÷Å©¸° È­»ý(¡­ûùßæ)
  • immature myeloid element
    ¹Ì¼÷°ñ¼ö¼º Ç÷__¡­ÍéâÐàõúìϹ).
  • immature myeloid element
    ¹Ì¼÷°ñ¼ö¼º Ç÷±¸(?Ë­ËàËÛÌ´Ë´).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • agnogenic myeloid metaplasia
    ¿øÀκҸíÀÇ °ñ¼öÈ­»ýÁõ.
  • agnogenic(idiopathic) myeloid metaplasia
    ¿øÀκҸí(Ư¹ß¼º) °ñ¼öÈ­»ýÁõ(ê«ì×ÝÕÙ¥ ÍéâÐûùßæñø)
  • aleukemic myelosis=myelofibrosis with myeloid metaplasia
    ¹«¹éÇ÷¼º °ñ¼öÁõ
  • myelofibrosis with myeloid metaplasia
    °ñ¼ö¾çÈ­»ý(åÆûùßæ)°ñ¼ö¼¶À¯Áõ
  • myeloid metaplasia
    °ñ¼ö¾çÈ­»ý(¡­åÆûùßæ)
  • myelosclerosis with myeloid metaplasia
    °ñ¼ö¾çÈ­»ý°ñ¼ö°æÈ­Áõ
  • apocrine metaplasia
    ¾ÆÆ÷Å©¸° È­»ý(¡­ûùßæ)
  • cell,metaplasia
    È­»ý(ûùßæ)
  • metaplasia
    È­»ý
  • metaplasia
    È­»ý
  • nephrogenic metaplasia
    ½Å¼ºÈ­»ý(ãìàõûùßæ)
  • squamous metaplasia
    ÆíÆò»óÇÇÈ­»ý
  • squamous metaplasia
    ÆíÆò»óÇÇÈ­»ý(¡­ûùßæ)
  • symptomatic
    ÁõÈļº(ñøý¦àõ)ÀÇ, Áõ»ó(ñøßÒ)ÀÇ, ´ëÁõ(Óßñø)ÀÇ.
  • symptomatic alopecia ³ª a. symptomatica
    ÁõÈļº Å»¸ðÁõ(ñøý¦àõ÷­Ù¾ñø)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Myeloid tissue
    °ñ¼öÁ¶Á÷
    [¿¾ ¿ë¾î] °ñ¼ö¾çÁ¶Á÷
  • Myeloid tissue
    °ñ¼öÁ¶Á÷ [»À¼ÓÁúÁ¶Á÷]
    [¿¾ ¿ë¾î] °ñ¼ö¾çÁ¶Á÷
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • metaplasia
    È­»ý, ÀÌÇü¼º
  • symptomatic
    ÁõÈļºÀÇ, Áõ»óÀÇ, ´ëÁßÀÇ
  • symptomatic asthma
    ÁõÈļºÃµ½Ä
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MMM see 3-M [syndrome]; microsome-mediated mutagenesis; myelofibrosis with myeloid metaplasia; myeloscle...
AMM Agnogenic Myeloid Metaplasia
MF   1) Myelo-Fibrosis
    = Agnogenic Myeloid Metaplasia with Myelo-F...
AMM agnogenic myeloid metaplasia; ammonia; antibody to murine cardiac myosin; World Medical Association ...
MM macromolecule; Maelzels metronome; major medical [insurance]; malignant melanoma; manubrium to malle...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AMM Agnogenic myeloid metaplasia
MMM Myelofibrosis with Myeloid Metaplasia
NASCET North American Symptomatic Carotid Endarteectomy Trial
IM Intestinal Metaplasia
SCM secretory cell metaplasia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • agnogenic idiopathic myeloid metaplasia
    ¿øÀÎ ºÒ¸í Ư¹ß¼º °ñ¼ö È­»ýÁõ
  • supportive and symptomatic therapy
    Áõ»ó ¿ä¹ý
  • symptomatic anemia
    ÁõÈļº ºóÇ÷
  • immature myeloid precussor
    ¹Ì¼º¼÷ °ñ¼ö ¼¼Æ÷
  • myeloid
    °ñ¼ö¼º, °ñ¼öÁõ, °ñ¼ö¾çÀÇ
  • myeloid leukoses
    °ñ¼ö¼º ¹éÇ÷Áõ
  • cartilaginous metaplasia
    ¿¬°ñ È­»ý
    ¿¬°ñ Á¶Á÷ÀÇ ¼º¼÷¼¼Æ÷°¡ ±× Á¶Á÷¿¡¼­´Â Á¤»óÀÌ ¾Æ´Ñ ÇüÀ¸·Î º¯È­µÇ´Â °Í.
  • direct metaplasia
    Á÷Á¢ È­»ý
  • metaplasia
    ÀÌÇü¼º, È­»ý
    ÇÑ ÇüÅÂÀÇ Á¶Á÷ÀÌ ±× Á¶Á÷¿¡¼­´Â ºñÁ¤»óÀÎ Á¶Á÷À¸·Î º¯ÇÏ´Â °Í.
  • osseous metaplasia
    °ñ È­»ý
  • squamous metaplasia
    ÆíÆò »óÇÇ·Î ÀÌÇü¼º, ÆíÆò È­»ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
symptomatic myeloid metaplasia Myeloid metaplasia occurring in individuals with another disease.
Synonym: symptomatic myeloid metaplasia.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
agnogenic myeloid metaplasia A progressive disease of the bone marrow where neoplastic bone marrow stem cells lodge and grow in multiple sites outside the bone marrow. Typically, there is enlargement of the spleen and a gradual replacement of the bone marrow elements by fibrosis (scarring), progressive anaemia and variable changes in the number of white blood cells and platelets.
Diagnosis is by bone marrow biopsy. There is no definitive treatment for this disorder that has been shown to affect life span favorably.
Origin: Gr. Plassein = to form
(27 Sep 1997)
myeloid metaplasia A progressive disease of the bone marrow where neoplastic bone marrow stem cells lodge and grow in multiple sites outside the bone marrow. Typically, there is enlargement of the spleen and a gradual replacement of the bone marrow elements by fibrosis (scarring), progressive anaemia and variable changes in the number of white blood cells and platelets.
Diagnosis is by bone marrow biopsy. There is no definitive treatment for this disorder that has been shown to affect life span favorably.
Origin: Gr. Plassein = to form
(27 Sep 1997)
primary myeloid metaplasia Myeloid metaplasia occurring as the primary condition, often in association with myelofibrosis.
Synonym: agnogenic myeloid metaplasia.
(05 Mar 2000)
secondary myeloid metaplasia Myeloid metaplasia occurring in individuals with another disease.
Synonym: symptomatic myeloid metaplasia.
(05 Mar 2000)
acute myeloid leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
apocrine metaplasia Alteration of acinar epithelium of breast tissue to resemble apocrine sweat glands; seen commonly in fibrocystic disease of the breasts.
(05 Mar 2000)
autoparenchymatous metaplasia Metaplasia occurring in the parenchymal cells proper to the tissue.
(05 Mar 2000)
celomic metaplasia theory of endometriosis That endometrial tissue arises directly from the peritoneal mesothelium.
(05 Mar 2000)
metaplasia <oncology, pathology> The change in the type of adult cells in a tissue to a form which is not formal for that tissue.
Origin: Gr. Plassein = to form
(18 Nov 1997)
chronic myeloid leukaemia <haematology> A leukaemia which is initially slowly-progressing. There are approximately 650 new cases each year in the UK. It is characterised by the presence of large numbers of abnormal mature granulocytes, circulating in the blood.
Synonym: chronic granulocytic leukaemia.
Acronym: CML
Origin: Gr. Haima = blood
(12 Jan 1998)
coelomic metaplasia Potential of coelomic epithelium to differentiate into several different histologic cell types.
(05 Mar 2000)
myeloid Collective term for the nonlymphocyte groups of white blood cells. It includes cells from the granulocyte, monocyte and platelet lineages.
(13 Nov 1997)
myeloid cell <haematology, pathology> One of the two classes of marrow derived blood cells, includes megakaryocytes, erythrocyte precursors, mononuclear phagocytes and all the polymorphonuclear granulocytes. That all these are ultimately derived from one stem cell lineage is shown by the occurrence of the Philadelphia chromosome in these, but not lymphoid, cells. most authors tend, however, to restrict the term myeloid to mononuclear phagocytes and granulocytes and commonly distinguish a separate erythroid lineage.
(12 May 1997)
myeloid sarcoma <tumour> A malignant tumour of immature myeloid cells, frequently subperiosteal, associated with or preceding granulocytic leukaemia.
See: chloroma.
Synonym: myeloid sarcoma.
(05 Mar 2000)
myeloid series The granulocytic and the erythrocytic series.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • symptomatic
    ¡Èĸ¦ ³ªÅ¸³»´Â
  • symptomatic
    ¡ÈÄÀûÀÎ;Á¶ÁüÀÇ;ÀüÁ¶°¡ µÇ´Â;...À» ³ªÅ¸³»´Â(indicative)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á